Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.280
-0.060-1.12%
Volume:446.12K
Turnover:2.39M
Market Cap:4.30B
PE:-22.57
High:5.550
Open:5.190
Low:5.190
Close:5.340
52wk High:9.560
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:1.25
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.234
ROE:-3.45%
ROA:-1.93%
PB:1.02
PE(LYR):-22.57
PS:3.94

Loading ...

Novartis Secures New Chinese Approval for Key Radiopharmaceutical Therapy

Stock News
·
Aug 26

Shenyang Cracks Down on Illegal Veterinary Drug Sales: Two Stores Under Investigation

Deep News
·
Aug 24

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Stock News
·
Aug 21

Huiyu Pharma's Aesthetic Medicine Expansion Stalls: Subsidiary Insolvency and Funding Model Expose Multiple Hazards

Deep News
·
Aug 21

Historic mRNA Cancer Vaccine Breakthrough Sends Pharmaceutical Stocks Soaring on US, A-share, and HK Markets

Deep News
·
Aug 20

BAIYUNSHAN PH Secures Regulatory Approval for Citicoline Sodium Injection New Dosage Strengths

Stock News
·
Aug 19

Penalty Finalized for Nanxin Pharmaceutical Over Disclosure Violations, Affected Investors Invited to Register Claims

Deep News
·
Aug 19

China's AI-Driven Drug Discovery Sector Poised for Clinical Breakthroughs and Commercial Growth, Analyst Says

Stock News
·
Aug 19

Zejing Pharma Seeks Hong Kong Listing After Turning Profitable, But Earnings Quality Raises Questions

Deep News
·
Aug 17

17 Drugmakers Announce Major Executive Reshuffles in Half a Month

Deep News
·
Aug 17

BAIYUNSHAN PH Subsidiary Secures Pharmaceutical Registration Certificate from Macau Health Regulator

Stock News
·
Aug 17

Fictitious Profits Equated to 157% of Total Reported Income: A 2023 Loss Was Masked as Gains for This Company, Affected Investors May Be Eligible for Claims

Deep News
·
Aug 17

Penalty on Nanyangxin Pharmaceutical Fuels Ongoing Investor Claims

Deep News
·
Aug 14

Ocumension Therapeutics Sets 28 August Board Meeting to Review 1H 2026 Results and Potential Interim Dividend

Bulletin Express
·
Aug 14

Ocumension Therapeutics Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 14

Zelgen Biopharma Makes Second Attempt at Hong Kong IPO Amid Insider Selling and Related-Party Acquisition Concerns

Deep News
·
Aug 14

Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO

Stock News
·
Aug 13

Hong Kong Stock Movers: METIS TECHBIO-P Surges Over 7% Again, Accumulating Nearly 30% Gains Since Early August, Leading AI Drug Discovery Sector for Consecutive Days

Stock News
·
Aug 11

Ascletis-B Launches Two Phase 1 Obesity Studies in the United States

Stock News
·
Aug 10

AI-Driven Drug Discovery Nears Reality: From Molecule Generation to Clinical Validation

Deep News
·
Aug 10